Ninety One, Inc. Selects Rush University Medical Center’s Kousik Krishnan, M.D. FACC to Join the Medical Advisory Board

Chicago to Play a Key Role In The Advancement of Artificial Intelligence in the Field of Cardiology

NEW YORK--(BUSINESS WIRE)--Ninety One, Inc., an augmented intelligence company developing innovative software and data science solutions designed to automate cardiac remote monitoring and further Precision Medicine, announced today that Rush University Medical Center’s Dr. Kousik Krishnan joined its Medical Advisory Board.

“I am thrilled to welcome Dr. Kousik Krishnan!” said Bleron Baraliu, Co-founder and CEO of Ninety One. “His depth of knowledge and experience in electrical and biomedical engineering and research in signal processing authenticate his commitment to innovative medicine on the basis of progressive mathematical modelling and artificial intelligence. As we grow the significance of our proprietary models in AI, Dr. Krishnan’s experience in a world-class academic center like Rush, coupled with his long standing vision and passion for predictive algorithms in medicine, will play a critical role in Ninety One’s aspiration to boost Precision Medicine efforts into a new paradigm of digital healthcare,” Bleron added.

“Ninety One has built a team and system that leverages the power of modern computing. It will advance the field of CIED monitoring by utilizing artificial intelligence to aggregate data in a way that will be intuitive for CIED clinics and reduce the burden of these checks on healthcare providers. Beyond this, there is a tremendous amount of data in these CIEDs that have the power to predict disease episodes and disease progression. I am honored to join this team to help utilize advanced computational principles to improve patient's quality of life, improve mortality, and reduce the CIED clinic burden on healthcare providers,” said Dr. Krishnan.

“We are delighted that Dr. Krishnan is joining our Medical Advisory Board at this important time in the adoption of Digital Cardiology. As we begin our rapid adoption throughout academia in the U.S. and Europe, we believe Dr. Krishnan’s clinical expertise and visionary ideas give us a definite advantage to clinical operations, ” commented Matthew Werner, Chief Commercial Officer at Ninety One.

About Ninety One

Ninety One is a privately-held, data science and native-cloud technology company, focusing on clinical advancement in predictive analytics and Precision Medicine, and has established key, exclusive partnerships with leading research and healthcare institutions in the United States, Europe, and Asia.

For more information please visit https://www.91.life